E. R. Squibb Sons, Inc.

Medarex Inc.

Bristol-myers Squibb Compnay

Li-Sheng Lu

Haichun Huang

Chin Pan

Jonathan Alexander Terrett

Alan J Korman

Mark J Selby

Alison Witte

Heidi N Leblanc

Mark Yamanaka

Dapeng Yao

Mohan Srinivasan

David J King

Josephine M Cardarelli

Guodong Chen

Richard Y Huang

Shrikant Deshpande

Ekaterina G Deyanova

Jun Zhang

Tim Sproul

Timothy W Sproul

Marco A Coccia

Jonathan Alexander Terret

David John King

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

Anti-CD27 antibodies and uses thereof

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.

Human monoclonal antibodies to O8E

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.

Treating lung cancer using human monoclonal antibodies to protein tyrosine kinase 7 (PTK7)

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.

Monoclonal antibodies against Glypican-3

Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7)

Monoclonal antibodies against glypican-3

Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.

Human monoclonal antibodies to CD70

Growing community of inventors

Mountain View, CA, United States of America

Li-Sheng Lu